TIL therapy meets primary endpoint of progression-free survival in melanoma


The Netherlands Cancer Institute and the National Center for Cancer Immune Therapy, Department of Oncology, of the Copenhagen University Hospital (CCIT-DK) announced the primary results from the phase 3 M14TIL trial evaluating infusion of autologous in vitro expanded tumor-infiltrating lymphocytes (TILs) versus ipilimumab in patients with unresectable or metastatic melanoma. The trial met its primary endpoint of progression-free survival (PFS). Follow up for secondary endpoints is ongoing.  

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.